Merck KGaA Drops Lipoprotein(a) Heart Drug After Novartis Trial Failure, Leaving Fewer Drugs in Testing for High Lp(a)
Merck KGaA will not advance zerlasiran into late-stage testing after Novartis' pelacarsen lowered Lp(a) but failed to reduce heart attacks, strokes or deaths.
Medical Daily ·